在线观看人与动牲交视频_夜夜高潮次次欢爽AV女_奇米在线视频观看_欧美精品七区_色悠久久综合网_少妇潮喷无码白浆水视频

 威海威高      
山東威高集團醫用高分子制品股份有限公司（「本公司」）及其附屬公司（「本集團」）主要從事研發、生產及銷售醫用耗材、骨科材料、心臟支架等。本公司為國家高技術研究發展（863）計劃成果產業化基地、國家級高新技術企業。本集團主要生產基地位于山東省威海市。

本集團在中國注冊，擁有一個由18個銷售辦事處及21個客戶聯絡中心和107多家城市代表處組成的龐大銷售網絡，并已建立廣泛的客戶基礎，其產品銷售予5,400多家醫療單位和分銷商，其中包括醫院2800多家、血站400多家、其它醫療單位700多家和逾1,500家貿易公司。

本集團生產的產品種類多達150余種，產品規格超過5000種，產品可分為六大系列，即1）一次性使用醫療耗材及原料，其中包括輸液（血）器、注射器、血袋與血液成份分離耗材、采血系列耗材、齒科耗材和麻醉系列耗材等，以及醫用PVC粒料和非PVC粒料等；2)骨科材料及工具，主要包括鋼板、螺釘等創傷治療耗材、脊柱系列耗材及正在發展的人工關節系列耗材；3)醫用針制品，主要包括靜脈針、注射針、留置針、采血針、異形針等系列制品；4)血液凈化系列耗材，主要包括穿刺針、血液回路管、透析器等腎科耗材，以及用于紅斑狼瘡、器官移植排異反應、類風濕關節炎等免疫系統疾病治療的免疫吸附柱，以及其它正在研發和注冊的LDL吸附柱、內毒素吸附柱和乙肝病毒吸附柱等；5)心臟支架產品，主要包括藥物涂層心臟支架、球囊等；6)用于藥品包裝的預充式注射器。

“國家高技術研究發展（863）計劃成果產業化基地”、“國家級企業技術中心”，并建有企業博士后工作站。公司積極開展產、學、研合作，與中科院長春應用化學研究所、中科院大連化學物理研究所、中科院沈陽金屬研究所、第三軍醫大學、301醫院、哈工大（威海）等科研院所、院校緊密合作，并聘請了10位兩院院士做顧問，依托其人才和科研力量，異地建立了九個威高集團研發中心，立足行業制高點，消化吸收國際前沿技術，開發具有自主知識產權的高科技產品。公司有60多個產品達到國內外先進水平，不少產品填補了國內空白，20個產品入選國家863計劃、國家重點火炬計劃、國家高技術產業示范化工程、國家級重點新產品等國家各類項目，其中藥物涂層支架系統、預充式注射器、骨科植入材料等產品打破了國外公司對中國市場的壟斷。

集團注重產品品牌的長遠發展，強調其產品質量。自2001年11月以來，集團的一次性使用無菌輸液器、一次性使用無菌輸血器及一次性使用無菌注射器的生產及服務的質量體系獲中國醫療器械質量認證中心授予ISO9001：2000認證、中國CMD認證。從1999年12月，集團的輸液器、輸血器、一次性使用注射器及塑料血袋等產品種類獲得由TüV Product Service Gmbh頒發的CE認證證書以來，本集團已先后獲得一次性使用自動取血器、一次性使用CT增強注射器造影劑針筒、一次性使用自毀式安全注射器、自動縮回式安全注射器、骨科器械、金屬接骨板，脊柱內固定系統，金屬接骨螺釘、帶鎖髓內釘、一次性使用無菌注射針、一次性使用靜脈留置針、無針密閉輸液接頭等產品及體系的CE認證。于2003年12月5日，集團的產品質量檢查中心獲中國實驗室國家認可委員會評為符合國家測試及定標規定。于2005年6月23日，集團擁有的 商標被中國國家工商行政管理總局認定為中國國內醫療器械行業第一個中國馳名商標。

目前，集團的銷售主要在中國市場，本集團正積極開拓國際市場，產品已經出口美國、德國、羅馬尼亞、澳大利亞和英國等30個國家和地區。
威海威高坐落在美麗的海濱城市威海。集團下轄18個子公司，其中山東威高集團醫用高分子制品股份有限公司為香港上市公司，已經形成了醫療器械、藥品、航天電子、投資、房地產等五大業務領域齊頭并進的發展格局。集團現有總資產40多億元，員工9000多人，廠區占地面積125萬平方米，擁有符合GMP要求的凈化車間20多萬平方米，可生產300多個品種近30000種規格的醫療器械、藥品等產品。

20年來，威高堅持“開拓、創新、求實、鞏固”的建廠方針，以科技創新為動力，以科學管理為后盾，促進了企業的持續、快速、健康發展。公司較早在國內開發了一次性使用輸注耗材、手術縫合線、植入性醫用導管、心臟支架、留置針及各種異型針、血液凈化系列產品、骨科系列產品、機電一體化醫療器械、治療型注射液、生物診斷試劑、人造血漿等醫療器械產品和藥品，建立了極具規模的醫療用品工業園、骨科材料工業園、醫藥科技工業園、航天電子產品生產基地，現已成為中國最大的一次性使用醫療器械制造商。

威高集團堅持“以人為本、科技先行”的發展戰略，健全科學的管理模式，完善管理體系。公司在同行業中率先引進和使用ERP、KPI等先進管理軟件，產品通過了CE、ISO9001、ISO13485、3C等認證，部分產品通過了美國FDA上市許可。公司的檢測中心通過了國家實驗室認可委員會的認可。對科技的執著追求，使威高集團獲得了生存發展空間。公司被國家科技部等部委確定為“國家火炬計劃重點高新技術企業”、“國家高技術研究發展（863）計劃成果產業化基地”、“國家級企業技術中心”，并建有企業博士后工作站。公司積極開展產、學、研合作，與中科院長春應用化學研究所、中科院大連化學物理研究所、中科院沈陽金屬研究所、第三軍醫大學、301醫院、哈工大（威海）等科研院所、院校緊密合作，并聘請了10位兩院院士做顧問，依托其人才和科研力量，異地建立了九個威高集團研發中心，立足行業制高點，消化吸收國際前沿技術，開發具有自主知識產權的高科技產品。公司有60多個產品達到國內外先進水平，不少產品填補了國內空白，20個產品入選國家863計劃、國家重點火炬計劃、國家高技術產業示范化工程、國家級重點新產品等國家各類項目，其中藥物涂層支架系統、預充式注射器、骨科植入材料等產品打破了國外公司對中國市場的壟斷。

威高集團堅持不懈地實施名牌戰略，培育知名品牌?！皾嵢稹鄙虡吮徽J定為“中國馳名商標”，“潔瑞牌一次性使用無菌輸注醫療器械”被授予“中國名牌產品”稱號，“潔瑞”品牌被中國品牌研究院評定為中國醫療器械第一品牌。公司在全國30多個省、市、自治區建立了100多個銷售辦事機構，同全國7000多家醫院、400多家血站、1800多家商業公司建立了長期穩定的關系。公司產品不僅暢銷到國內30多個省、市、自治區，還直接出口到美國、歐盟、俄羅斯、南非、巴西等50多個國家和地區。

威高集團將始終如一地堅持科學發展觀，以“攜同白衣使者，開創健康未來”為宗旨，以一次性醫療器械和藥品為主導，大力推進產業結構、產品結構、體制結構的調整，實現資本、技術和管理的國際化，矢志成為具世界競爭力、亞洲領先、最受人尊敬的醫療器械和醫藥企業，為促進我國醫療事業發展，提高人民健康水平做出新的貢獻。

Weigao Holding Company Limited. (“Weigao Holding”) and together with its subsidiaries (“Weigao”)is situated in Weihai City, a picturesque coastal city in China. Weigao Holding has 18 subsidiaries and has more than 9,000 employees and a total asset value of over RMB 4 billion (approximately US$0.59 billion). Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”), the major subsidiary of Weigao Holding, was listed on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited in 2004. Weigao covers a manufacturing area of 1,250,000 square meters including sterilized workshops with an area of 200,000 square meters that comply with GMP standards. It currently produces more than 250 types of medical products with more than 30,000 specifications.

In the past 20 years, Weigao rooted with the spirit of “development, innovation, pragmatism and consolidation”, and dedicated to attract talented people from the communities. Weigao focuses on technology driven innovative ideas and scientific management to transform the development mode and to advance the healthy and efficient growth of the business. In the domestic market, the company was the early mover to initiate the products of single use transfusion sets, medical suture, implantable medical catheters, coronary stents, intravenous catheters, irregular needles, blood purification, orthopaedic, electronic and mechanical medical products, medical injection fluid products, diagnostic reagents, artificial blood plasma and various medical products and medications. Weigao has established very large manufacturing bases in China for medical consumables, orthopaedic products, pharmaceuticals，and aerospace products. Today, Weigao is the leading single use medical consumable manufacturer in China.

Weigao established the mode of scientific management to achieve a smooth operation system. It is the first company in the industry to introduce and to successfully establish the management system of enterprise resource planning (ERP), key performance indicators (KPI) and other management system. Weigao Holding obtained the certifications of Conformité Européene (CE), ISO9000, ISO13485, China Compulsory Certification; and products registration of FDA 510K from Food and Drug Association (FDA). The award accredited to testing and inspection center of the company is also the only certification issued by China National Accreditation Board for Lab oratories in industry.

Weigao is devoted to innovation, technology and people and its commitment to technology is the value to its development. Weigao was accredited by the State Science and Technology Commission as the “Key High Technology & New Technological Enterprise under the State Torch Program”, the “Preferred Manufacturing Base for New Products Developed by the State High Technology Research Development (863) Program, and the technology center was also notarized by national governmental authorization as “State Enterprise Technology Center”. Weigao continues to develop into a conglomerate enterprise comprising of duties and responsibilities of manufacturing, education and research. The company established a post-doctoral research working center and collaborated with scientific research institutions and universities with strong scientific and research strength in setting up nine research and development centers. Ten academicians were appointed as consultants. There are more than 60 types of products which are further developed to enhance to an international level, and many of which filled the domestic blank. The company engaged in more than 20 national projects including Project 863, Project Torch, Model Project of National High Tech, The Key Technology Innovation Program of the State, and other projects. Currently, Weigao plays roles in the market of drug eluting stent (DES), pre-filled syringes and orthopedic material which were previously dominated by international players.

Weigao has been persistently sustain its brand value . The “Jierui” trademark is notarized by State Administration for Industry & Commerce as “China Famous Brand”; the “Jierui Single Use Sterile Infusion and Syringe Medical Device” was accredited by General Administration of Quality Supervision, Inspection and Quarantine of China as “the Most Famous Branded Product in China”; it is also notarized by China Brand Academy as “The No.1 Trademark” in the industry. Weigao has an extensive coverage of over 100 representative offices in 30 provinces, municipality and autonomous regions in China. Long term reliable relationship has also been well established with more than 7,000 hospitals, over 400 blood stations, and over 1800 other medical units. Today, Weigao’s products are not just the best-selling products in the domestic market; they are also exported to more than 50 countries and regions, including the United States, European countries, Russia, South Africa, and Brazil.

Weigao will continue to strive without reserve for the scientific development, and the mission is to “work with physicians to create healthy life for people in future”. Weigao will continue to improve and adjust the business structure, products mix and organizational structure. The goal of Weigao is to gradually transform from a domestic manufacturer to an internationally competitive, leading in Asia, and respectable conglomerate. Weigao, standing as a leading medical device company, continues to create and sustain a high level of performance in medical device products and pharmaceuticals. Weigao is well-positioned to continuing serving the medical community and improve people’s health for generations to come.